-
December 21, 2011
Sanofi has emerged as an unheralded value in pharmaceuticals.
-
December 02, 2011
A top hedge-fund manager venting his angst at President Obama is deeply conflicted and possibly delusional, writes ...
-
November 30, 2011
When a company like Novartis comes down the road with a healthy pipeline, the Street seems to respond with worries.
-
November 10, 2011
Medicis is well-run, but arguably too risky to stay independent.
-
November 01, 2011
Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
-
October 31, 2011
Once a go-go growth stock, a more reasonable valuation may give this stock new life.
-
August 17, 2011
In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors.
-
August 12, 2011
The price you pay for a stock determines the return you will make from investing in that company.
-
August 04, 2011
These two generics companies seem to be heading in opposite directions, but the values are similar.
-
July 28, 2011
Over the next five years, the market for "biosimilars" is forecast to climb to $10 billion worldwide, as many ...
-
July 28, 2011
Express Scripts is taking a bold move to become a titan of its industry.
-
July 19, 2011
Cubist is hitting its targets, but it needs a more exciting pipeline.
-
July 15, 2011
Transcept gets a major setback, but it may not be doomed.
-
July 06, 2011
Valuations look decent for many prescription drug companies.
-
July 05, 2011
The TICK blends the best of both the developed and developing nations.
-
June 10, 2011
With Lipitor coming off its patent soon, there are a couple of drug companies looking to cash in on sales of the ...
-
May 06, 2011
Mylan is not the biggest or the best, but the valuation here makes it worth a look.
-
May 06, 2011
The healthcare sector is still a bargain - and that alone should keep it in investors' minds.
-
May 04, 2011
Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
-
April 26, 2011
Teva's stock has taken a beating, but the next five years are likely to be tough.
